APO Research
Talk to an analyst

APO RESEARCH · REPORT

Therapeutic Nuclear Medicines

Radioactive material, called radiopharmaceuticals, can be used to treat certain conditions. This is called nuclear medicine therapy.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Radioactive material, called radiopharmaceuticals, can be used to treat certain conditions. This is called nuclear medicine therapy.

Therapeutic nuclear medicines are a pharmaceutical formulation that consists of radioactive substances (radioisotopes). Therapeutic nuclear medicines are intending for the treatment of cancer, metastatic bone pain and other diseases. The radioactive material of therapeutic nuclear medicines is capable of killing the cancerous tissue, reducing the size of a tumor and reducing pain.

Selected research

Market Outlook & Growth Opportunities

Global Therapeutic Nuclear Medicines Market Outlook and Growth Opportunities 2026

21 December 2025199 pages

Choose your research edition.

Industry ResearchTherapeutic Nuclear Medicines Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Therapeutic Nuclear Medicines Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Therapeutic Nuclear Medicines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Therapeutic Nuclear Medicines Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Therapeutic Nuclear Medicines Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

Radioactive material, called radiopharmaceuticals, can be used to treat certain conditions. This is called nuclear medicine therapy.

Therapeutic nuclear medicines are a pharmaceutical formulation that consists of radioactive substances (radioisotopes). Therapeutic nuclear medicines are intending for the treatment of cancer, metastatic bone pain and other diseases. The radioactive material of therapeutic nuclear medicines is capable of killing the cancerous tissue, reducing the size of a tumor and reducing pain.

Global Therapeutic Nuclear Medicines key players include Bayer, Novartis AG, China Isotope & Radiation, etc. Global top three manufacturers hold a share over 75%.

Read the full market overview

North America is the largest market, with a share about 45%, followed by Europe and Asia-Pacific, both have a share about 50 percent.

In terms of product, Radium-223 is the largest segment, with a share over 45%. And in terms of application, the largest application is Thyroid, followed by Bone Metastasis.

This report provides an overview of the global Therapeutic Nuclear Medicines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Therapeutic Nuclear Medicines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Therapeutic Nuclear Medicines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Therapeutic Nuclear Medicines market size, projected growth trends, production technologies, key applications, and end-use industries.

Therapeutic Nuclear Medicines Segment by Company

Novartis AG

Bayer

China Isotope & Radiation

Q BioMed

Curium Pharmaceuticals

Jubilant DraxImage

Dongcheng

Lantheus

Acrotech Biopharma.

Progenics Pharmaceuticals

International Isotopes

Therapeutic Nuclear Medicines Segment by Type

Radium-223

Lutetium-177

Iodine-131

Other

Therapeutic Nuclear Medicines Segment by Application

Thyroid

Bone Metastasis

Lymphoma

Other

Therapeutic Nuclear Medicines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Therapeutic Nuclear Medicines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Therapeutic Nuclear Medicines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Therapeutic Nuclear Medicines significant trends, drivers, influence factors in global and regions.

6. To analyze Therapeutic Nuclear Medicines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Nuclear Medicines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Nuclear Medicines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Nuclear Medicines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Therapeutic Nuclear Medicines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Therapeutic Nuclear Medicines industry.

Chapter 3: Detailed analysis of Therapeutic Nuclear Medicines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Therapeutic Nuclear Medicines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Therapeutic Nuclear Medicines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Therapeutic Nuclear Medicines Industry Trends Table 2. Therapeutic Nuclear Medicines Industry Drivers Table 3. Therapeutic Nuclear Medicines Industry Opportunities and Challenges Table 4. Therapeutic Nuclear Medicines Industry Restraints Table 5. Global Therapeutic Nuclear Medicines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Therapeutic Nuclear Medicines Revenue Share by Company (2021-2026) Table 7. Global Therapeutic Nuclear Medicines Sales Volume by Company (k units) & (2021-2026) Table 8. Global Therapeutic Nuclear Medicines Sales Volume Share by Company (2021-2026) Table 9. Global Therapeutic Nuclear Medicines Average Price (USD/unit) of Company (2021-2026) Table 10. Global Therapeutic Nuclear Medicines Company Ranking, (2024-2026) & (USD Million) Table 11. Global Therapeutic Nuclear Medicines Key Company Manufacturing Base & Headquarters Table 12. Global Therapeutic Nuclear Medicines Company, Product Type & Application Table 13. Global Therapeutic Nuclear Medicines Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Therapeutic Nuclear Medicines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Radium-223 Table 18. Significant Companies of Lutetium-177 Table 19. Significant Companies of Iodine-131 Table 20. Significant Companies of Other Table 21. Global Therapeutic Nuclear Medicines Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Therapeutic Nuclear Medicines Sales Volume by Type (2021-2026) & (k units) Table 23. Global Therapeutic Nuclear Medicines Sales Volume by Type (2027-2032) & (k units) Table 24. Global Therapeutic Nuclear Medicines Sales Volume Share by Type (2021-2026) Table 25. Global Therapeutic Nuclear Medicines Sales Volume Share by Type (2027-2032) Table 26. Global Therapeutic Nuclear Medicines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Therapeutic Nuclear Medicines Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Therapeutic Nuclear Medicines Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Therapeutic Nuclear Medicines Sales Value Share by Type (2021-2026) Table 30. Global Therapeutic Nuclear Medicines Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Thyroid Table 32. Significant Companies of Bone Metastasis Table 33. Significant Companies of Lymphoma Table 34. Significant Companies of Other Table 35. Global Therapeutic Nuclear Medicines Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global Therapeutic Nuclear Medicines Sales Volume by Application (2021-2026) & (k units) Table 37. Global Therapeutic Nuclear Medicines Sales Volume by Application (2027-2032) & (k units) Table 38. Global Therapeutic Nuclear Medicines Sales Volume Share by Application (2021-2026) Table 39. Global Therapeutic Nuclear Medicines Sales Volume Share by Application (2027-2032) Table 40. Global Therapeutic Nuclear Medicines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Therapeutic Nuclear Medicines Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Therapeutic Nuclear Medicines Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Therapeutic Nuclear Medicines Sales Value Share by Application (2021-2026) Table 44. Global Therapeutic Nuclear Medicines Sales Value Share by Application (2027-2032) Table 45. Global Therapeutic Nuclear Medicines Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 46. Global Therapeutic Nuclear Medicines Sales by Region (2021-2026) & (k units) Table 47. Global Therapeutic Nuclear Medicines Sales Market Share by Region (2021-2026) Table 48. Global Therapeutic Nuclear Medicines Sales by Region (2027-2032) & (k units) Table 49. Global Therapeutic Nuclear Medicines Sales Market Share by Region (2027-2032) Table 50. Global Therapeutic Nuclear Medicines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Therapeutic Nuclear Medicines Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Therapeutic Nuclear Medicines Sales Value Share by Region (2021-2026) Table 53. Global Therapeutic Nuclear Medicines Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Therapeutic Nuclear Medicines Sales Value Share by Region (2027-2032) Table 55. Global Therapeutic Nuclear Medicines Market Average Price (USD/unit) by Region (2021-2026) Table 56. Global Therapeutic Nuclear Medicines Market Average Price (USD/unit) by Region (2027-2032) Table 57. Global Therapeutic Nuclear Medicines Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 58. Global Therapeutic Nuclear Medicines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Therapeutic Nuclear Medicines Sales by Country (2021-2026) & (k units) Table 60. Global Therapeutic Nuclear Medicines Sales Market Share by Country (2021-2026) Table 61. Global Therapeutic Nuclear Medicines Sales by Country (2027-2032) & (k units) Table 62. Global Therapeutic Nuclear Medicines Sales Market Share by Country (2027-2032) Table 63. Global Therapeutic Nuclear Medicines Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Therapeutic Nuclear Medicines Sales Value Market Share by Country (2021-2026) Table 65. Global Therapeutic Nuclear Medicines Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Therapeutic Nuclear Medicines Sales Value Market Share by Country (2027-2032) Table 67. Novartis AG Company Information Table 68. Novartis AG Business Overview Table 69. Novartis AG Therapeutic Nuclear Medicines Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 70. Novartis AG Therapeutic Nuclear Medicines Product Portfolio Table 71. Novartis AG Recent Development Table 72. Bayer Company Information Table 73. Bayer Business Overview Table 74. Bayer Therapeutic Nuclear Medicines Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 75. Bayer Therapeutic Nuclear Medicines Product Portfolio Table 76. Bayer Recent Development Table 77. China Isotope & Radiation Company Information Table 78. China Isotope & Radiation Business Overview Table 79. China Isotope & Radiation Therapeutic Nuclear Medicines Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 80. China Isotope & Radiation Therapeutic Nuclear Medicines Product Portfolio Table 81. China Isotope & Radiation Recent Development Table 82. Q BioMed Company Information Table 83. Q BioMed Business Overview Table 84. Q BioMed Therapeutic Nuclear Medicines Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 85. Q BioMed Therapeutic Nuclear Medicines Product Portfolio Table 86. Q BioMed Recent Development Table 87. Curium Pharmaceuticals Company Information Table 88. Curium Pharmaceuticals Business Overview Table 89. Curium Pharmaceuticals Therapeutic Nuclear Medicines Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 90. Curium Pharmaceuticals Therapeutic Nuclear Medicines Product Portfolio Table 91. Curium Pharmaceuticals Recent Development Table 92. Jubilant DraxImage Company Information Table 93. Jubilant DraxImage Business Overview Table 94. Jubilant DraxImage Therapeutic Nuclear Medicines Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 95. Jubilant DraxImage Therapeutic Nuclear Medicines Product Portfolio Table 96. Jubilant DraxImage Recent Development Table 97. Dongcheng Company Information Table 98. Dongcheng Business Overview Table 99. Dongcheng Therapeutic Nuclear Medicines Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 100. Dongcheng Therapeutic Nuclear Medicines Product Portfolio Table 101. Dongcheng Recent Development Table 102. Lantheus Company Information Table 103. Lantheus Business Overview Table 104. Lantheus Therapeutic Nuclear Medicines Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 105. Lantheus Therapeutic Nuclear Medicines Product Portfolio Table 106. Lantheus Recent Development Table 107. Acrotech Biopharma. Company Information Table 108. Acrotech Biopharma. Business Overview Table 109. Acrotech Biopharma. Therapeutic Nuclear Medicines Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 110. Acrotech Biopharma. Therapeutic Nuclear Medicines Product Portfolio Table 111. Acrotech Biopharma. Recent Development Table 112. Progenics Pharmaceuticals Company Information Table 113. Progenics Pharmaceuticals Business Overview Table 114. Progenics Pharmaceuticals Therapeutic Nuclear Medicines Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 115. Progenics Pharmaceuticals Therapeutic Nuclear Medicines Product Portfolio Table 116. Progenics Pharmaceuticals Recent Development Table 117. International Isotopes Company Information Table 118. International Isotopes Business Overview Table 119. International Isotopes Therapeutic Nuclear Medicines Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 120. International Isotopes Therapeutic Nuclear Medicines Product Portfolio Table 121. International Isotopes Recent Development Table 122. Key Raw Materials Table 123. Raw Materials Key Suppliers Table 124. Therapeutic Nuclear Medicines Distributors List Table 125. Therapeutic Nuclear Medicines Customers List Table 126. Research Programs/Design for This Report Table 127. Authors List of This Report Table 128. Secondary Sources Table 129. Primary Sources List of Figures Figure 1. Therapeutic Nuclear Medicines Product Image Figure 2. Global Therapeutic Nuclear Medicines Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Therapeutic Nuclear Medicines Sales Value (2021-2032) & (US$ Million) Figure 4. Global Therapeutic Nuclear Medicines Sales (2021-2032) & (k units) Figure 5. Global Therapeutic Nuclear Medicines Sales Average Price (USD/unit) & (2021-2032) Figure 6. Global Therapeutic Nuclear Medicines Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Radium-223 Image Figure 10. Lutetium-177 Image Figure 11. Iodine-131 Image Figure 12. Other Image Figure 13. Global Therapeutic Nuclear Medicines Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Therapeutic Nuclear Medicines Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Therapeutic Nuclear Medicines Sales Volume Share by Type (2021-2032) Figure 16. Global Therapeutic Nuclear Medicines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Therapeutic Nuclear Medicines Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Therapeutic Nuclear Medicines Sales Value Share by Type (2021-2032) Figure 19. Thyroid Image Figure 20. Bone Metastasis Image Figure 21. Lymphoma Image Figure 22. Other Image Figure 23. Global Therapeutic Nuclear Medicines Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Therapeutic Nuclear Medicines Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Therapeutic Nuclear Medicines Sales Volume Share by Application (2021-2032) Figure 26. Global Therapeutic Nuclear Medicines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Therapeutic Nuclear Medicines Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Therapeutic Nuclear Medicines Sales Value Share by Application (2021-2032) Figure 29. Global Therapeutic Nuclear Medicines Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 30. Global Therapeutic Nuclear Medicines Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Therapeutic Nuclear Medicines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Therapeutic Nuclear Medicines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Therapeutic Nuclear Medicines Sales Value (2021-2032) & (US$ Million) Figure 34. North America Therapeutic Nuclear Medicines Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Therapeutic Nuclear Medicines Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Therapeutic Nuclear Medicines Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Therapeutic Nuclear Medicines Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Therapeutic Nuclear Medicines Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Therapeutic Nuclear Medicines Sales Value (2021-2032) & (US$ Million) Figure 40. South America Therapeutic Nuclear Medicines Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Therapeutic Nuclear Medicines Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Therapeutic Nuclear Medicines Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Therapeutic Nuclear Medicines Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Therapeutic Nuclear Medicines Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Radium-223
  • Lutetium-177
  • Iodine-131
  • Other
Applications
  • Thyroid
  • Bone Metastasis
  • Lymphoma
  • Other
Companies covered
  • Novartis AG
  • Bayer
  • China Isotope & Radiation
  • Q BioMed
  • Curium Pharmaceuticals
  • Jubilant DraxImage
  • Dongcheng
  • Lantheus
  • Acrotech Biopharma.
  • Progenics Pharmaceuticals
  • International Isotopes

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Therapeutic Nuclear Medicines Sales Value (2021-2032)
  4. 1.2.2 Global Therapeutic Nuclear Medicines Sales Volume (2021-2032)
  5. 1.2.3 Global Therapeutic Nuclear Medicines Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Therapeutic Nuclear Medicines Market Dynamics
  1. 2.1 Therapeutic Nuclear Medicines Industry Trends
  2. 2.2 Therapeutic Nuclear Medicines Industry Drivers
  3. 2.3 Therapeutic Nuclear Medicines Industry Opportunities and Challenges
  4. 2.4 Therapeutic Nuclear Medicines Industry Restraints
3 Therapeutic Nuclear Medicines Market by Company
  1. 3.1 Global Therapeutic Nuclear Medicines Company Revenue Ranking in 2025
  2. 3.2 Global Therapeutic Nuclear Medicines Revenue by Company (2021-2026)
  3. 3.3 Global Therapeutic Nuclear Medicines Sales Volume by Company (2021-2026)
  4. 3.4 Global Therapeutic Nuclear Medicines Average Price by Company (2021-2026)
  5. 3.5 Global Therapeutic Nuclear Medicines Company Ranking (2024-2026)
  6. 3.6 Global Therapeutic Nuclear Medicines Company Manufacturing Base and Headquarters
  7. 3.7 Global Therapeutic Nuclear Medicines Company Product Type and Application
  8. 3.8 Global Therapeutic Nuclear Medicines Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Therapeutic Nuclear Medicines Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Therapeutic Nuclear Medicines Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Therapeutic Nuclear Medicines Market by Type
  1. 4.1 Therapeutic Nuclear Medicines Type Introduction
  2. 4.1.1 Radium-223
  3. 4.1.2 Lutetium-177
  4. 4.1.3 Iodine-131
  5. 4.1.4 Other
  6. 4.2 Global Therapeutic Nuclear Medicines Sales Volume by Type
  7. 4.2.1 Global Therapeutic Nuclear Medicines Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Therapeutic Nuclear Medicines Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Therapeutic Nuclear Medicines Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Therapeutic Nuclear Medicines Sales Value by Type
  11. 4.3.1 Global Therapeutic Nuclear Medicines Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Therapeutic Nuclear Medicines Sales Value by Type (2021-2032)
  13. 4.3.3 Global Therapeutic Nuclear Medicines Sales Value Share by Type (2021-2032)
5 Therapeutic Nuclear Medicines Market by Application
  1. 5.1 Therapeutic Nuclear Medicines Application Introduction
  2. 5.1.1 Thyroid
  3. 5.1.2 Bone Metastasis
  4. 5.1.3 Lymphoma
  5. 5.1.4 Other
  6. 5.2 Global Therapeutic Nuclear Medicines Sales Volume by Application
  7. 5.2.1 Global Therapeutic Nuclear Medicines Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Therapeutic Nuclear Medicines Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Therapeutic Nuclear Medicines Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Therapeutic Nuclear Medicines Sales Value by Application
  11. 5.3.1 Global Therapeutic Nuclear Medicines Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Therapeutic Nuclear Medicines Sales Value by Application (2021-2032)
  13. 5.3.3 Global Therapeutic Nuclear Medicines Sales Value Share by Application (2021-2032)
6 Therapeutic Nuclear Medicines Regional Sales and Value Analysis
  1. 6.1 Global Therapeutic Nuclear Medicines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Therapeutic Nuclear Medicines Sales by Region (2021-2032)
  3. 6.2.1 Global Therapeutic Nuclear Medicines Sales by Region: 2021-2026
  4. 6.2.2 Global Therapeutic Nuclear Medicines Sales by Region (2027-2032)
  5. 6.3 Global Therapeutic Nuclear Medicines Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Therapeutic Nuclear Medicines Sales Value by Region (2021-2032)
  7. 6.4.1 Global Therapeutic Nuclear Medicines Sales Value by Region: 2021-2026
  8. 6.4.2 Global Therapeutic Nuclear Medicines Sales Value by Region (2027-2032)
  9. 6.5 Global Therapeutic Nuclear Medicines Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Therapeutic Nuclear Medicines Sales Value (2021-2032)
  12. 6.6.2 North America Therapeutic Nuclear Medicines Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Therapeutic Nuclear Medicines Sales Value (2021-2032)
  15. 6.7.2 Europe Therapeutic Nuclear Medicines Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Therapeutic Nuclear Medicines Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Therapeutic Nuclear Medicines Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Therapeutic Nuclear Medicines Sales Value (2021-2032)
  21. 6.9.2 South America Therapeutic Nuclear Medicines Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Therapeutic Nuclear Medicines Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Therapeutic Nuclear Medicines Sales Value Share by Country, 2025 VS 2032
7 Therapeutic Nuclear Medicines Country-level Sales and Value Analysis
  1. 7.1 Global Therapeutic Nuclear Medicines Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Therapeutic Nuclear Medicines Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Therapeutic Nuclear Medicines Sales by Country (2021-2032)
  4. 7.3.1 Global Therapeutic Nuclear Medicines Sales by Country (2021-2026)
  5. 7.3.2 Global Therapeutic Nuclear Medicines Sales by Country (2027-2032)
  6. 7.4 Global Therapeutic Nuclear Medicines Sales Value by Country (2021-2032)
  7. 7.4.1 Global Therapeutic Nuclear Medicines Sales Value by Country (2021-2026)
  8. 7.4.2 Global Therapeutic Nuclear Medicines Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Therapeutic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Therapeutic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Therapeutic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG Therapeutic Nuclear Medicines Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG Therapeutic Nuclear Medicines Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 Bayer
  8. 8.2.1 Bayer Company Information
  9. 8.2.2 Bayer Business Overview
  10. 8.2.3 Bayer Therapeutic Nuclear Medicines Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Bayer Therapeutic Nuclear Medicines Product Portfolio
  12. 8.2.5 Bayer Recent Developments
  13. 8.3 China Isotope & Radiation
  14. 8.3.1 China Isotope & Radiation Company Information
  15. 8.3.2 China Isotope & Radiation Business Overview
  16. 8.3.3 China Isotope & Radiation Therapeutic Nuclear Medicines Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 China Isotope & Radiation Therapeutic Nuclear Medicines Product Portfolio
  18. 8.3.5 China Isotope & Radiation Recent Developments
  19. 8.4 Q BioMed
  20. 8.4.1 Q BioMed Company Information
  21. 8.4.2 Q BioMed Business Overview
  22. 8.4.3 Q BioMed Therapeutic Nuclear Medicines Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Q BioMed Therapeutic Nuclear Medicines Product Portfolio
  24. 8.4.5 Q BioMed Recent Developments
  25. 8.5 Curium Pharmaceuticals
  26. 8.5.1 Curium Pharmaceuticals Company Information
  27. 8.5.2 Curium Pharmaceuticals Business Overview
  28. 8.5.3 Curium Pharmaceuticals Therapeutic Nuclear Medicines Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Curium Pharmaceuticals Therapeutic Nuclear Medicines Product Portfolio
  30. 8.5.5 Curium Pharmaceuticals Recent Developments
  31. 8.6 Jubilant DraxImage
  32. 8.6.1 Jubilant DraxImage Company Information
  33. 8.6.2 Jubilant DraxImage Business Overview
  34. 8.6.3 Jubilant DraxImage Therapeutic Nuclear Medicines Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Jubilant DraxImage Therapeutic Nuclear Medicines Product Portfolio
  36. 8.6.5 Jubilant DraxImage Recent Developments
  37. 8.7 Dongcheng
  38. 8.7.1 Dongcheng Company Information
  39. 8.7.2 Dongcheng Business Overview
  40. 8.7.3 Dongcheng Therapeutic Nuclear Medicines Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Dongcheng Therapeutic Nuclear Medicines Product Portfolio
  42. 8.7.5 Dongcheng Recent Developments
  43. 8.8 Lantheus
  44. 8.8.1 Lantheus Company Information
  45. 8.8.2 Lantheus Business Overview
  46. 8.8.3 Lantheus Therapeutic Nuclear Medicines Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Lantheus Therapeutic Nuclear Medicines Product Portfolio
  48. 8.8.5 Lantheus Recent Developments
  49. 8.9 Acrotech Biopharma.
  50. 8.9.1 Acrotech Biopharma. Company Information
  51. 8.9.2 Acrotech Biopharma. Business Overview
  52. 8.9.3 Acrotech Biopharma. Therapeutic Nuclear Medicines Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Acrotech Biopharma. Therapeutic Nuclear Medicines Product Portfolio
  54. 8.9.5 Acrotech Biopharma. Recent Developments
  55. 8.10 Progenics Pharmaceuticals
  56. 8.10.1 Progenics Pharmaceuticals Company Information
  57. 8.10.2 Progenics Pharmaceuticals Business Overview
  58. 8.10.3 Progenics Pharmaceuticals Therapeutic Nuclear Medicines Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Progenics Pharmaceuticals Therapeutic Nuclear Medicines Product Portfolio
  60. 8.10.5 Progenics Pharmaceuticals Recent Developments
  61. 8.11 International Isotopes
  62. 8.11.1 International Isotopes Company Information
  63. 8.11.2 International Isotopes Business Overview
  64. 8.11.3 International Isotopes Therapeutic Nuclear Medicines Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 International Isotopes Therapeutic Nuclear Medicines Product Portfolio
  66. 8.11.5 International Isotopes Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Therapeutic Nuclear Medicines Value Chain Analysis
  2. 9.1.1 Therapeutic Nuclear Medicines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Therapeutic Nuclear Medicines Sales Mode & Process
  6. 9.2 Therapeutic Nuclear Medicines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Therapeutic Nuclear Medicines Distributors
  9. 9.2.3 Therapeutic Nuclear Medicines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst